Characterization of the Symptom Experience of Patients with Cutaneous Melanoma Receiving Immune Checkpoint Inhibitor Therapy

Inclusion Criteria

• Patients will be included if they are: adults ≥18 years of age; able to speak and read English; diagnosed with stage IIB, III, or IV cutaneous melanoma; will receive ≥ 1 immune checkpoint inhibitor; and provide written informed consent to participate in this study. Patients on targeted therapies (e.g., BRAF or MEK inhibitors) will be eligible. Recruitment is restricted to patients with stage IIB or higher cutaneous melanoma because immune checkpoint inhibitor therapy is only FDA-approved for these patients.

Exclusion Criteria

• Patients will be excluded if they are unable to complete study requirements.